Skip to main content
. 2017 Mar 10;8(16):27481–27488. doi: 10.18632/oncotarget.16078

Figure 1. Incremental cost-effectiveness ratio of antihypertensive monotherapy.

Figure 1

Incremental cost-effectiveness ratio (USD·mmHg−1) of angiotensin II-targeted drugs, calcium channel blockers and diuretics was presented among CIDEC rs1053239 (A) and rs2479 (B) genotypes. Incremental cost-effectiveness ratio of antihypertensive drugs for each genotype was calculated as indicated in Statistical analysis.